文献速递前列腺癌

黑人男性中年基线PSA水平与侵袭性前列腺癌风险

Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
PubMed 文献 · Eur Urol · 2018-09-17

该嵌套病例对照研究纳入南方社区队列研究中197例黑人前列腺癌患者和569例对照,发现中年基线PSA水平强烈预测黑种人男性总前列腺癌和侵袭性前列腺癌风险;对照组的PSA水平与既往白人研究相似。基于中年PSA的靶向筛查或可识别高风险男性并减少低风险者筛查。

要点

  • 黑人男性中年基线PSA可强烈预测未来侵袭性前列腺癌风险。
  • 对照人群年龄别PSA中位数与既往白人对照研究相似。
  • 基于中年PSA的靶向筛查策略可能优化黑人男性筛查。

核心结论

  • 在黑人男性中,中年基线PSA水平强烈预测总前列腺癌和侵袭性前列腺癌风险。

研究设计与样本

  • 南方社区队列研究(2002—2009年招募)中的嵌套病例对照研究,纳入197例40—64岁入射前列腺癌患者和569例按年龄、采血日期和入组站点匹配的对照。

主要发现

  • 对照组PSA中位数在40—49、50—54、55—59、60—64岁组分别为0.72、0.80、0.94、1.03ng/ml,第90百分位分别为1.68、1.85、2.73、3.33ng/ml。
  • 95%的总前列腺癌病例和97%的侵袭性病例基线PSA高于年龄别中位数。
  • 中位随访9年,PSA>第90百分位对比≤中位数的总前列腺癌OR在40—54岁为83.6(95%CI 21.2—539),55—64岁为71.7(95%CI 23.3—288)。
  • 侵袭性前列腺癌OR在40—54岁为174(95%CI 32.3—无穷),55—64岁为51.8(95%CI 11.0—519)。

临床怎么用

  • 对黑人男性可考虑基于中年PSA水平进行风险分层,以识别侵袭性前列腺癌高风险者并减少低风险者的筛查。

局限性

  • 侵袭性前列腺癌采用基于分期、分级和死亡率的复合终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific antigen (PSA) measurement in midlife predicts long-term prostate cancer (PCa) mortality among white men. OBJECTIVE: To determine whether baseline PSA level during midlife predicts risk of aggressive PCa in black men. DESIGN, SETTING, AND PARTICIPANTS: Nested case-control study among black men in the Southern Community Cohort Study recruited between 2002 and 2009. A prospective cohort in the southeastern USA with recruitment from community health centers. A total of 197 incident PCa patients aged 40-64 yr at study entry and 569 controls matched on age, date of blood draw, and site of enrollment. Total PSA was measured in blood collected and stored at enrollment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Total and aggressive PCa (91 aggressive: Gleason ≥7, American Joint Committee on Cancer stage III/IV, or PCa-specific death). Exact conditional logistic regression estimated odds ratios (ORs) with 95% confidence intervals (CIs) for PCa by category of baseline PSA. RESULTS AND LIMITATIONS: Median PSA among controls was 0.72, 0.80, 0.94, and 1.03ng/ml for age groups 40-49, 50-54, 55-59, and 60-64 yr, respectively; 90th percentile levels were 1.68, 1.85, 2.73, and 3.33ng/ml. Furthermore, 95% of total and 97% of aggressive cases had baseline PSA above the age-specific median. Median follow-up was 9 yr. The OR for total PCa comparing PSA >90th percentile versus ≤median was 83.6 (95% CI, 21.2-539) for 40-54 yr and 71.7 (95% CI, 23.3-288) for 55-64 yr. For aggressive cancer, ORs were 174 (95% CI, 32.3-infinity) for 40-54 yr and 51.8 (95% CI, 11.0-519) for 55-64 yr. A composite endpoint of aggressive PCa based on stage, grade, and mortality was used and is a limitation. CONCLUSIONS: PSA levels in midlife strongly predicted total and aggressive PCa among black men. PSA levels among controls were similar to those among white controls in prior studies. PATIENT SUMMARY: Prostate-specific antigen (PSA) level during midlife strongly predicted future development of aggressive prostate cancer among black men. Targeted screening based on a midlife PSA might identify men at high risk while minimizing screening in those men at low risk.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Preston MA, Gerke T, Carlsson SV, et al. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Eur Urol. 2018. PMID: 30237027. doi:10.1016/j.eururo.2018.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。